RxDoctor Payments Data

Hiral Shah, MD

Gastroenterology · Allentown, PANPI 1093862666

Payments from drug & device makers

$75,612in general payments, 2019–2025

Across 80 payments — averaging $945.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$72K
  • ERBE USA Inc$2K
  • US Endoscopy$1K
  • Boston Scientific$682
  • Nestle Healthcare Nutrition Inc.$124
  • Johnson & Johnson$114
  • plus $402 from 7 others

What the payments were for

  • Consulting fees$3,1004%
  • Speaking & faculty fees$64,25085%
  • Travel & lodging$3,2844%
  • Food & beverage$3,4785%
  • Education$1,5002%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)57$71,790
ERBE USA Inc1$1,500
US Endoscopy1$1,000
Boston Scientific11$682
Nestle Healthcare Nutrition Inc.1$124
Johnson & Johnson1$114
Medtronic1$101
Apollo Endosurgery US Inc1$100
Covidien LP1$100
Steris Corporation1$53
Aimmune Therapeutics, Inc.2$33
Novus Surgical Consultants1$14
Endogastric Solutions, Inc1$1

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,612 in reported general payments places this provider in the 90th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$119,979
Medicare patients
405
Services billed
1,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase12$38,338
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates37$2,466
Sucralfate25$2,011
Omeprazole60$1,013
Dicyclomine Hcl14$548
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl29$458
Pantoprazole Sodium36$406
Famotidine30$263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$71,790$38,33812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →